M3RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction

Raman Deep Singh, Matthew L. Hillestad, Christopher Livia, Mark Li, Alexey E. Alekseev, Tyra A. Witt, Paul G. Stalboerger, Satsuki Yamada, Andre Terzic, Atta Behfar

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Myocardial infarction occurs every 36 s or nearly 1 million times in the United States. The treatment of acute myocardial infarction (AMI) has been revolutionized with coronary reperfusion ensuring over 96% in-hospital survival. There has, however, been a paucity in technological advancement in the field of acute coronary syndrome, with nearly 30% of individuals progressing toward heart failure after AMI. This has engendered a pandemic of ischemic heart failure worldwide, mandating the development of off-the-shelf regenerative interventions, including gene-encoded therapies, capable to acutely target the injured myocardium. However, the main challenge in realizing gene-encoded therapy for AMI has been the inadequate induction of gene expression following intracoronary delivery. To address this challenge, we, in this study, report the use of synthetic modified messenger RNA, engineered to reduce lag time. Termed M3RNA (microencapsulated modified messenger RNA), this platform achieved expeditious induction of protein expression in cell lines (HEK293, human dermal and cardiac fibroblasts) and primary cardiomyocytes. Expression was documented as early as 2-4 h and lasted up to 7 days without impact on electromechanical coupling, as tracked by patch clamp electrophysiology and calcium imaging in transfected cardiomyocytes. In vivo, firefly luciferase (FLuc) and mCherry M3RNA myocardial injections in mice using ∼100 nm nanoparticles yielded targeted and temporally restricted expression of FLuc protein within 2 h, and sustained for 72 h as assessed by Xenogen and mCherry expression using immunofluorescence. In a porcine model of myocardial infarction, protein expression targeted to the area of injury was demonstrated following intracoronary delivery of alginate carrying M3RNA encoding mCherry. M3RNA thus enables rapid protein expression in primary cardiomyocytes and targeted expression in mouse and porcine hearts. This novel technology, capable of inducing rapid simultaneous protein expression, offers a platform to achieve targeted gene-based therapies in the setting of AMI. The M3RNA (microencapsulated modified messenger RNA) platform is an approach to deliver messenger RNA (mRNA) in vivo, achieving a nonintegrating and viral-free approach to gene therapy. This technology was, in this study, tested for its utility in the myocardium, providing a unique avenue for targeted gene delivery into the freshly infarcted myocardial tissue. This study provides the evidentiary basis for the use of M3RNA in the heart through depiction of its performance in cultured cells, healthy rodent myocardium, and acutely injured porcine hearts. By testing the technology in large animal models of infarction, compatibility of M3RNA with current coronary intervention procedures was verified.

Original languageEnglish (US)
Pages (from-to)145-158
Number of pages14
JournalTissue Engineering - Part A
Volume25
Issue number1-2
DOIs
StatePublished - Jan 1 2019

Fingerprint

Gene therapy
Genes
Myocardial Infarction
Proteins
Genetic Therapy
Firefly Luciferases
Messenger RNA
Cardiac Myocytes
Myocardium
Swine
Technology
Cells
Electrophysiology
Heart Failure
Electromechanical coupling
Alginate
Clamping devices
Fibroblasts
Myocardial Reperfusion
Gene expression

Keywords

  • gene therapy
  • M3RNA
  • myocardial infarction
  • targeted nucleotide delivery

ASJC Scopus subject areas

  • Bioengineering
  • Biochemistry
  • Biomaterials
  • Biomedical Engineering

Cite this

Singh, R. D., Hillestad, M. L., Livia, C., Li, M., Alekseev, A. E., Witt, T. A., ... Behfar, A. (2019). M3RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction. Tissue Engineering - Part A, 25(1-2), 145-158. https://doi.org/10.1089/ten.tea.2017.0445

M3RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction. / Singh, Raman Deep; Hillestad, Matthew L.; Livia, Christopher; Li, Mark; Alekseev, Alexey E.; Witt, Tyra A.; Stalboerger, Paul G.; Yamada, Satsuki; Terzic, Andre; Behfar, Atta.

In: Tissue Engineering - Part A, Vol. 25, No. 1-2, 01.01.2019, p. 145-158.

Research output: Contribution to journalArticle

Singh, RD, Hillestad, ML, Livia, C, Li, M, Alekseev, AE, Witt, TA, Stalboerger, PG, Yamada, S, Terzic, A & Behfar, A 2019, 'M3RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction', Tissue Engineering - Part A, vol. 25, no. 1-2, pp. 145-158. https://doi.org/10.1089/ten.tea.2017.0445
Singh RD, Hillestad ML, Livia C, Li M, Alekseev AE, Witt TA et al. M3RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction. Tissue Engineering - Part A. 2019 Jan 1;25(1-2):145-158. https://doi.org/10.1089/ten.tea.2017.0445
Singh, Raman Deep ; Hillestad, Matthew L. ; Livia, Christopher ; Li, Mark ; Alekseev, Alexey E. ; Witt, Tyra A. ; Stalboerger, Paul G. ; Yamada, Satsuki ; Terzic, Andre ; Behfar, Atta. / M3RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction. In: Tissue Engineering - Part A. 2019 ; Vol. 25, No. 1-2. pp. 145-158.
@article{89cd78a0cddb4b6b803d5431a2d6c659,
title = "M3RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction",
abstract = "Myocardial infarction occurs every 36 s or nearly 1 million times in the United States. The treatment of acute myocardial infarction (AMI) has been revolutionized with coronary reperfusion ensuring over 96{\%} in-hospital survival. There has, however, been a paucity in technological advancement in the field of acute coronary syndrome, with nearly 30{\%} of individuals progressing toward heart failure after AMI. This has engendered a pandemic of ischemic heart failure worldwide, mandating the development of off-the-shelf regenerative interventions, including gene-encoded therapies, capable to acutely target the injured myocardium. However, the main challenge in realizing gene-encoded therapy for AMI has been the inadequate induction of gene expression following intracoronary delivery. To address this challenge, we, in this study, report the use of synthetic modified messenger RNA, engineered to reduce lag time. Termed M3RNA (microencapsulated modified messenger RNA), this platform achieved expeditious induction of protein expression in cell lines (HEK293, human dermal and cardiac fibroblasts) and primary cardiomyocytes. Expression was documented as early as 2-4 h and lasted up to 7 days without impact on electromechanical coupling, as tracked by patch clamp electrophysiology and calcium imaging in transfected cardiomyocytes. In vivo, firefly luciferase (FLuc) and mCherry M3RNA myocardial injections in mice using ∼100 nm nanoparticles yielded targeted and temporally restricted expression of FLuc protein within 2 h, and sustained for 72 h as assessed by Xenogen and mCherry expression using immunofluorescence. In a porcine model of myocardial infarction, protein expression targeted to the area of injury was demonstrated following intracoronary delivery of alginate carrying M3RNA encoding mCherry. M3RNA thus enables rapid protein expression in primary cardiomyocytes and targeted expression in mouse and porcine hearts. This novel technology, capable of inducing rapid simultaneous protein expression, offers a platform to achieve targeted gene-based therapies in the setting of AMI. The M3RNA (microencapsulated modified messenger RNA) platform is an approach to deliver messenger RNA (mRNA) in vivo, achieving a nonintegrating and viral-free approach to gene therapy. This technology was, in this study, tested for its utility in the myocardium, providing a unique avenue for targeted gene delivery into the freshly infarcted myocardial tissue. This study provides the evidentiary basis for the use of M3RNA in the heart through depiction of its performance in cultured cells, healthy rodent myocardium, and acutely injured porcine hearts. By testing the technology in large animal models of infarction, compatibility of M3RNA with current coronary intervention procedures was verified.",
keywords = "gene therapy, M3RNA, myocardial infarction, targeted nucleotide delivery",
author = "Singh, {Raman Deep} and Hillestad, {Matthew L.} and Christopher Livia and Mark Li and Alekseev, {Alexey E.} and Witt, {Tyra A.} and Stalboerger, {Paul G.} and Satsuki Yamada and Andre Terzic and Atta Behfar",
year = "2019",
month = "1",
day = "1",
doi = "10.1089/ten.tea.2017.0445",
language = "English (US)",
volume = "25",
pages = "145--158",
journal = "Tissue Engineering - Part A",
issn = "1937-3341",
publisher = "Mary Ann Liebert Inc.",
number = "1-2",

}

TY - JOUR

T1 - M3RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction

AU - Singh, Raman Deep

AU - Hillestad, Matthew L.

AU - Livia, Christopher

AU - Li, Mark

AU - Alekseev, Alexey E.

AU - Witt, Tyra A.

AU - Stalboerger, Paul G.

AU - Yamada, Satsuki

AU - Terzic, Andre

AU - Behfar, Atta

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Myocardial infarction occurs every 36 s or nearly 1 million times in the United States. The treatment of acute myocardial infarction (AMI) has been revolutionized with coronary reperfusion ensuring over 96% in-hospital survival. There has, however, been a paucity in technological advancement in the field of acute coronary syndrome, with nearly 30% of individuals progressing toward heart failure after AMI. This has engendered a pandemic of ischemic heart failure worldwide, mandating the development of off-the-shelf regenerative interventions, including gene-encoded therapies, capable to acutely target the injured myocardium. However, the main challenge in realizing gene-encoded therapy for AMI has been the inadequate induction of gene expression following intracoronary delivery. To address this challenge, we, in this study, report the use of synthetic modified messenger RNA, engineered to reduce lag time. Termed M3RNA (microencapsulated modified messenger RNA), this platform achieved expeditious induction of protein expression in cell lines (HEK293, human dermal and cardiac fibroblasts) and primary cardiomyocytes. Expression was documented as early as 2-4 h and lasted up to 7 days without impact on electromechanical coupling, as tracked by patch clamp electrophysiology and calcium imaging in transfected cardiomyocytes. In vivo, firefly luciferase (FLuc) and mCherry M3RNA myocardial injections in mice using ∼100 nm nanoparticles yielded targeted and temporally restricted expression of FLuc protein within 2 h, and sustained for 72 h as assessed by Xenogen and mCherry expression using immunofluorescence. In a porcine model of myocardial infarction, protein expression targeted to the area of injury was demonstrated following intracoronary delivery of alginate carrying M3RNA encoding mCherry. M3RNA thus enables rapid protein expression in primary cardiomyocytes and targeted expression in mouse and porcine hearts. This novel technology, capable of inducing rapid simultaneous protein expression, offers a platform to achieve targeted gene-based therapies in the setting of AMI. The M3RNA (microencapsulated modified messenger RNA) platform is an approach to deliver messenger RNA (mRNA) in vivo, achieving a nonintegrating and viral-free approach to gene therapy. This technology was, in this study, tested for its utility in the myocardium, providing a unique avenue for targeted gene delivery into the freshly infarcted myocardial tissue. This study provides the evidentiary basis for the use of M3RNA in the heart through depiction of its performance in cultured cells, healthy rodent myocardium, and acutely injured porcine hearts. By testing the technology in large animal models of infarction, compatibility of M3RNA with current coronary intervention procedures was verified.

AB - Myocardial infarction occurs every 36 s or nearly 1 million times in the United States. The treatment of acute myocardial infarction (AMI) has been revolutionized with coronary reperfusion ensuring over 96% in-hospital survival. There has, however, been a paucity in technological advancement in the field of acute coronary syndrome, with nearly 30% of individuals progressing toward heart failure after AMI. This has engendered a pandemic of ischemic heart failure worldwide, mandating the development of off-the-shelf regenerative interventions, including gene-encoded therapies, capable to acutely target the injured myocardium. However, the main challenge in realizing gene-encoded therapy for AMI has been the inadequate induction of gene expression following intracoronary delivery. To address this challenge, we, in this study, report the use of synthetic modified messenger RNA, engineered to reduce lag time. Termed M3RNA (microencapsulated modified messenger RNA), this platform achieved expeditious induction of protein expression in cell lines (HEK293, human dermal and cardiac fibroblasts) and primary cardiomyocytes. Expression was documented as early as 2-4 h and lasted up to 7 days without impact on electromechanical coupling, as tracked by patch clamp electrophysiology and calcium imaging in transfected cardiomyocytes. In vivo, firefly luciferase (FLuc) and mCherry M3RNA myocardial injections in mice using ∼100 nm nanoparticles yielded targeted and temporally restricted expression of FLuc protein within 2 h, and sustained for 72 h as assessed by Xenogen and mCherry expression using immunofluorescence. In a porcine model of myocardial infarction, protein expression targeted to the area of injury was demonstrated following intracoronary delivery of alginate carrying M3RNA encoding mCherry. M3RNA thus enables rapid protein expression in primary cardiomyocytes and targeted expression in mouse and porcine hearts. This novel technology, capable of inducing rapid simultaneous protein expression, offers a platform to achieve targeted gene-based therapies in the setting of AMI. The M3RNA (microencapsulated modified messenger RNA) platform is an approach to deliver messenger RNA (mRNA) in vivo, achieving a nonintegrating and viral-free approach to gene therapy. This technology was, in this study, tested for its utility in the myocardium, providing a unique avenue for targeted gene delivery into the freshly infarcted myocardial tissue. This study provides the evidentiary basis for the use of M3RNA in the heart through depiction of its performance in cultured cells, healthy rodent myocardium, and acutely injured porcine hearts. By testing the technology in large animal models of infarction, compatibility of M3RNA with current coronary intervention procedures was verified.

KW - gene therapy

KW - M3RNA

KW - myocardial infarction

KW - targeted nucleotide delivery

UR - http://www.scopus.com/inward/record.url?scp=85059326345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059326345&partnerID=8YFLogxK

U2 - 10.1089/ten.tea.2017.0445

DO - 10.1089/ten.tea.2017.0445

M3 - Article

VL - 25

SP - 145

EP - 158

JO - Tissue Engineering - Part A

JF - Tissue Engineering - Part A

SN - 1937-3341

IS - 1-2

ER -